Introduction: 20 J/501Y.V3) emerged in Brazil, contains mutations K417T, E484K and N501Y in the RBD with evidence to affect transmissibility and antigenic profile.
Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants.
Introduction: The recent emerging variants of concern observed in the United Kingdom (B.1.1.7 with mutations N501Y, A570D and del69/70), South Africa (B.1.351 with mutations K417N, E484K and N501Y), Brazil (P.1 and P.2 with mutations K417T, E484K and N501Y) (Long et al.) and India (B.1.617 with mutations L452R and E484Q) (Cherian et al.) initially respond more tightly to ACE2 and appear to be more infectious to human (Laffeber et al.; Tian et al.).
Discussion: Variants of concern observed in the United Kingdom (B.1.1.7 with mutations N501Y), South Africa (B.1.351 with mutations
A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type of the virus.
Result: Based on D614G, other mutations existing in RBD are K417N/K417T, E484K, and N501Y which might affect the recognition and binding of SARS-CoV-2 to ACE2.
Genomic monitoring unveil the early detection of the SARS-CoV-2 B.1.351 (beta) variant (20H/501Y.V2) in Brazil.
Result: P.1 defining mutations related to each genomic region were the following: ORF1ab: S1188L, K1795Q, E5665D; spike: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y, T1027I; Orf8: E92K; and nucleocapsid: P80.
Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2.
Method: Specifically, protein A (Sino Biological) was firstly covalently immobilized onto a CM5 sensor chip, followed by capture of the individual antibodies and then injection of purified soluble SARS-CoV-2 WT and K417R/A/E/N/T mutant RBDs at five different concentrations.
Result: K417A/E/N/T mutants resulted in complete resistance to P5A-3C8, P22A-1D1, and P5A-1D2 while remaining sensitive to P2C-1F11.
Result: K417A/E/N/T mutations disrupted these salt bridges, leading to loss of neutralizing activity.
Result: In contrast, K417A/E/N/T mutants substantially reduced binding by P22A-1D1 and P5A-1D2, while impact on P5A-3C8 and P2C-1F11 was relatively moderate.
Result: Of note, K417
SARS-CoV-2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?
Result: However, in this case, our results predict that both mutants (K417N and K417T) could destabilize the protein and increase local flexibility.
Table: K417T
SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom.
Introduction: The combination of nearby RBD mutations K417N/T, E484K and N501Y found in B.1.351 (South Africa) and P.1 (Brazil) make these particularly concerning variants.
Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies.
Abstract: We constructed nanobody tandems and identified nanobody monomers that tolerate the K417N/T, E484K, N501Y, and L452R immune-escape mutations found in the Alpha, Beta, Gamma, Epsilon, Iota, and Delta/Kappa lineages.
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants.
Introduction: The S genes of B.1.351 and P.1 viruses each carry a number of mutations, but include three in the receptor binding domain (RBD) that are particularly notable, the S: N501Y substitution, found in B.1.1.7, alongside polymorphisms at positions 417 and 484, K417N/T and E484K.
Discussion: B.1.351 and P.1 have in common three RBD substitutions (K417N/T, E484K and N501Y) whereas B.1.351, P.1 and B.1.1.7 contain the N501Y substitution.
The challenge of screening SARS-CoV-2 variants of concern with RT-qPCR: One variant can hide another.
PMID: 34332998
2021
Journal of virological methods
Abstract: From week 18 we used in addition the new NovaplexSARS-CoV-2 Variants II Assay for samples with no targets found with the Variants I assay or with the mutation E484K alone, in order to screen the mutations L452R, K417N/T
Discussion: It distinguishes the VOC B.1.351 from the VOC P.1 by amplification of the K417N and K417T mutations respectively when both the N501Y and E484K mutations were found positive with the Variant I Assay.
Discussion: Since early May 2021, a new NovaplexSARS-CoV-2 Variants II Assay has been available on the market to detect L452R, K417N, K417T and W152C mutations.
SARS_CoV_2 mutation literature information.
PMID: 
2021
Virology
Browser Board
Co-occurred Entities
Filtrator
ViMRT